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Background: Poor and inconsistent use of study products has hindered clinical
HIV prevention studies. It is important to be able to monitor product adherence and
protocol compliance in order to determine microbicide efficacy and safety more
accurately. Current methods for monitoring adherence are subjective, non-specific,
or invasive. Herein, we present a composite, objective measure of product
adherence and protocol compliance to assess vaginal insertion, semen exposure
and drug expulsion utilizing DNA, protein, and drug isolated directly from returned,
vaginally used gel applicators.
Methods: DNA, vaginal cells, and residual tenofovir were isolated from vaginally
inserted applicators. Vaginal and semen biomarkers were amplified using a
multiplex PCR to determine vaginal insertion. Vaginal cells were fixed followed by
cytokeratin 4 immunocytochemistry to confirm DNA assessment of vaginal
insertion. Tenofovir was extracted and quantitated through LC-MS/MS.
Results: DNA isolated from vaginally inserted applicators were positive for vaginal
bacteria DNA and the control eukaryotic gene, amelogenin, while manually
handled, ‘‘sham’’, applicators were negative for both. Semen exposure was
independently determined by simultaneous amplification of one or both Y-
chromosomal genes, SRY and TSPY4. Vaginal insertion determination by DNA
analysis was further confirmed by positive cytokeratin 4 (CK4)
immunocytochemistry of vaginal cells remaining on the gel applicators. On the
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contrary, sham applicators provided very few cells when swabbed, and they were
all negative for CK4. CK4 was not found in epidermal cells from the hand. Drug
expulsion was detected through quantitation of residual gel present on the surface
of returned applicators. Sham applicators had no detectable tenofovir.
Conclusion: Utilizing a composite, triple marker based panel of DNA, protein, and
drug present on the surface of returned vaginal gel applicators, it is possible to
determine, objectively and non-invasively, product adherence, protocol compliance,
and semen exposure in microbicide trials.
Introduction
More than 30 years into the epidemic, HIV infection remains a significant global
public health issue, particularly in resource constrained countries [1].
Microbicides are products that can be applied vaginally to help reduce the risk of
sexually transmitted infections (STIs), in particular HIV. This family of products
includes antiretroviral-based microbicides, which have been developed with the
intent to provide women with pre-exposure prophylaxis against HIV infection.
While there are discordant results on reduced HIV incidence among various HIV
prevention studies, protocol adherence data suggest that detection of drug in the
participants was always associated with efficacy [2]. The CAPRISA 004 trial in
South Africa investigating TFV 1% vaginal gel demonstrated an overall 39%
reduction in HIV incidence by intent-to-treat analysis with higher degree of
protection in women who used the product in more than 80% of the sex acts [3].
Furthermore, concentrations of tenofovir in cervicovaginal fluid in excess of
1000 ng/mL were associated with.70% protection [4, 5].
Poor adherence hinders interpretation of final data and leads to under-
estimation of drug efficacy. To further complicate this issue, there is ample
literature demonstrating that self-report of compliance almost always over-
estimates protocol and product adherence [6]. Current measures of adherence
include number of applicators collected [3], visual inspection of returned, used
applicators (VIRA) [7], dye stain assays (DSA) using trypan blue [8] or FD&C
Blue Dye No. 1 [9, 10], ultraviolet light illumination (UVL) of applicators [7, 11],
or electronic monitoring such as the Wisebag [11, 12]. While all have been
validated, each method is still limited by subjectivity or self-report on sexual
activity. For example, DSA and UVL measures vaginal insertion by visual
determination of positive staining or fluorescence of proteins in vaginal
secretions. Subjectivity and different levels of training of the readers hinders
consistent accuracy of adherence determination. The two tests are also not specific
enough to determine semen exposure independent of vaginal insertion. The
Wisebag monitors applicator use by electronically detecting when the bag is
opened. This approach does not provide information on the number of
applicators retrieved when the bag is opened. It also does not provide information
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as to whether applicators were retrieved around the time of coital activity. The
Wisebag approach as well as counting returned applicators still depends upon self-
report of sex acts in order to determine adherence. Finally, no current adherence
measurement can determine whether vaginal insertion equates to vaginal gel
explusion. To accurately determine appropriate gel applicator use as well as
potential semen exposure, which reflects HIV exposure and risk of infection, we
set out to identify objective, biological, and quantifiable markers of vaginal
insertion, semen exposure, and drug expulsion that could be measured directly
from used applicators with relative ease in a non-invasive manner.
For detection of vaginal insertion, we used vaginal bacterial DNA markers
amplified by PCR. The human vagina has a well described microbiota that helps
maintain a normal vaginal physiology and pH [13]. This microbiota has known
fluctuations which can be used for diagnostic purposes [14]. Changes due to
diseases like bacterial vaginosis have been detected through PCR amplification of
bacterial DNA isolated from vaginal swabs [15]. Forensic reports have
demonstrated the use of bacterial DNA for identification of vaginal fluids [16–18].
Although DNA is very stable and easily amplified, it is not always specific to a
cell type or anatomic location. This also applies to bacterial DNA. It is well
known, however, that differential expression of proteins can distinguish cellular
phenotypes. A previous study reported that epithelial cells isolated from vaginal
swabs expressed cytokeratin 4 (CK4) while those isolated from epidermal swabs
did not [19]. We therefore used immunocytochemical detection of CK4 as a
confirmatory marker of vaginal insertion. For semen detection, we previously
developed a multiplex PCR system, which amplifies two Y-chomosomal genes,
SRY (Sex-determining region in the Y chromosome) and TSPY4 (Testis-specific
protein Y encoded 4), and an internal control gene, amelogenin. These male-
specific genes can be detected in cervicovaginal swabs obtained from women up to
1 week post-semen exposure [20].
An additional requirement for correct product use is expulsion of product,
once the applicator is inserted into the vagina around coital activity. TFV in
human genital and colorectal tissue can be quantitated successfully by LC-MS/MS
analysis [21, 22]. Therefore, we determined whether residual TFV gel from
swabbed vaginally inserted applicators could be extracted and quantitated, as an
indication of gel expulsion.
In this report, we present proof-of-concept data for detecting vaginal insertion
and semen exposure using DNA and protein isolated from a single, vaginally
inserted applicator. These markers were validated against ‘‘sham’’ (uninserted
applicators) and epidermal cells from the hand. Completing the triple marker
panel of adherence, we also present feasibility data in measuring residual TFV
from the surface of vaginally inserted gel applicators.
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Materials and Methods
Human subject research ethics statement
De-identified, returned, used gel applicators were obtained from women
participating in two clinical trials utilizing either hydroxyethylcellulose (HEC)
placebo gel (CONRAD D13-125, #NCT01804023) or TFV 1% gel (CONRAD
A12-124, #NCT01810315) applicators. Both studies were approved by the
Chesapeake Institutional Review Board (Pro 00008154) and Eastern Virginia
Medical School (EVMS) Institutional Review Board (13-02-FB-0017), respec-
tively. All women provided an informed, written consent for use of the samples.
Semen was obtained with written, informed consent under a protocol approved
by the EVMS Institutional Review Board (#13-02-FB-0031).
Isolation of DNA and vaginal cells from vaginally inserted
applicators
De-identified hydroxyethylcellulose (HEC) or ‘‘placebo’’ gel applicators were used
for establishing the protocol to isolate DNA and vaginal cells on the applicator.
The CONRAD D13-125 study for which these applicators were obtained [23]
involved healthy HIV-negative women between the ages 18-50 whereby HEC gel
applicators were vaginally inserted by the clinical investigator. Some applicators
were inserted, removed, and HEC gel expelled into a waste container while some
applicators were inserted and gel vaginally expelled before removal. Other
applicators (‘‘sham’’) were manually handled without gloves by the participant.
The sham applicators were prepared by taking the applicator out of the package,
connecting the plunger, removing the cap, and expelling gel into a waste can
rather than inserting into the vagina. The applicator was then placed back in the
package.
In the research lab, applicators were swabbed with a double headed rayon
Starplex swab (Starplex Scientific, Cleveland, TN) (Fig. 1). The swab heads were
snapped apart, and one swab head was placed in a lysis buffer for DNA extraction
as previously described [20]. Briefly, the swab head in the lysis buffer was
incubated at 55 C̊ for 1 hour before extraction using the Qiagen DNA Mini kit
(Qiagen, Valencia CA). DNA was quantitated before using for PCR analysis. The
other swab head was used for isolating vaginal epithelial cells by a modified, but
previously described method [19]. The swabs were placed in 1 ml Cytorich Red
solution (Thermo- Scientific, Kalamazoo, MI) for 5 minutes. Swabs were then
removed and cell suspensions shaken for 10 minutes. The fixed cells were pelleted
by spinning at 5000 rpm for 10 minutes and resuspended in 20 mL Cytorich Red.
The cells were spotted onto slides at 5 mL and dried overnight for hematoxylin
and CK4 immunocytochemistry.
Vaginal–Semen multiplex PCR
The previously established multiplex PCR containing primers for Y-chromosomal
genes was expanded to include various primers specific for seven bacterial species
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prevalent in vaginal microbiota. Using published sequences [15, 24–26], the
primers shown in Table 1 were incorporated into the PCR protocol using the
Qiagen Multiplex Plus PCR Kit (Qiagen, Valencia, CA). DNA from vaginal swabs,
semen, or vaginally inserted gel applicators was used as template for the PCR. The
slightly modified cycling protocol was as follows: One cycle of 95 C̊ for 5 minutes,
35–40 cycles of 95 C̊ for 30 seconds, 60 C̊ for 90 seconds, 72 C̊ for 60 seconds, and
1 cycle of 68 C̊ for 10 minutes. After completion of the PCR cycles, the amplified
DNA products were analyzed using the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA) in conjunction with its DNA 1000 kit. PCR
products were visualized by placing 1 mL of the PCR reaction to the DNA
LabChip (Agilent Technologies, Santa Clara, CA) and placed in the 2100
Bioanalyzer, which provided the size and the concentration (ng/mL) of the
amplified PCR products in the 50 mL PCR reaction.
For testing the multiplex PCR using semen/sperm DNA as template, semen/
sperm was obtained from healthy, normozoospermic, non-vasectomized donors
under EVMS-approved IRB protocol #13-02-FB-003. The sperm DNA used in
this study was extracted from a pooled sample of 3 donors. Semen DNA was
extracted from 1 donor.
Cytokeratin immunocytochemistry
Slides spotted with vaginal cells obtained from swabbed gel applicators were
washed in 100%, 95%, and 70% ethanol sequentially, for 5 minutes each. After
final washes in dH2O and PBS, slides were blocked with 3% BSA for 30 minutes
Figure 1. IsolationofDNAandVaginalCells from InsertedGelApplicators.Vaginally inserted applicators or
sham applicators were swabbed with a double headed rayon swab (1) to which one head was placed in a lysis
buffer for DNA extraction and the other in Cytorich red for fixation of vaginal cells (2). The fixed vaginal cells
were spotted onto slides for cytokeratin 4 immunohistochemistry (3).
doi:10.1371/journal.pone.0114368.g001
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before adding 1:100 of a rabbit anti-human cytokeratin 4 primary antibody
(Abcam, Cambridge, MA) or 1:100 of a mouse anti-human cytokeratin 10 (Santa
Cruz, Dallas, TX) in blocking buffer for 1 hour. An equivalent amount of normal
rabbit or mouse IgG (Santa Cruz, Dallas, TX) was used as a negative control. After
two washes in PBS, 1:200 of a biotinylated goat anti-rabbit or goat anti-mouse IgG
secondary antibody (Vector Laboratories, Burlingame, CA) was incubated for 30
minutes. Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) in
combination with AEC chromagen (ScyTek Laboratories, Logan, UT) was used
for detection according to manufacturers’ instructions. Cells were counterstained
with hematoxylin before mounting in aqueous mounting media (DAKO,
Carpinteria, CA) and coverslipping.
Measurement of residual TFV on vaginally inserted applicators
TFV 1% gel applicators were obtained from an ongoing clinical study (CONRAD
A12-124) whereby premenopausal women between 21–45 years, in their homes,
vaginally inserted and expelled one gel applicator. Two hours later, they vaginally
inserted and expelled a second applicator to simulate the BAT24 dosing regimen
previously determined to successfully reduce HIV incidence in the CAPRISA 004
study [3]. To determine whether residual TFV on the external surface of the
applicators could be measured, a third swab head was incorporated into the lab
protocol described above. In this protocol, three swab heads were simultaneously
used to swab the surface of the applicator. While the original two heads were used
for DNA/CK4 biomarkers, the newly added swab head was frozen at 280 C̊ until
ready for LC-MS/MS analysis of TFV. Quantification of tenofovir was performed
by extracting the drug from calibration standards, quality control samples, and
study samples using protein precipitation and a stable labeled tenofovir as internal
standard. Tenofovir on swabs were solvated in 2mL, and 100 mL aliquots were
utilized for analysis. Tenofovir was eluted from a Waters Atlantis T3 (100x2,
1 mm, 3micron) analytical column with mobile phases consisting of formic acid,
acetonitrile and water, detected on an AB Sciex API-5000 triple quadrupole mass
spectrometer, and data collected with Sciex Analyst Chromatography Software.
The calibration range was 0.1 ng to 1,000 ng of tenofovir per swab, with intra-
and interday variability and precision of ,15% and ,10%, respectively.
Table 1. Vaginal Bacteria Primers for Multiplex PCR.
Species PCR Product [reference]
Lactobacillus gasseri 162 bp [25]
Prevotella buccalis-like 192 bp [25]
Megasphaera elsdenii-like (phylotype 1) 211 bp [24]
Eggerthella-like 238 bp [15]
BVAB1 261 bp [15]
Lactobacillus crispatus 571 bp [24]
Lactobacillus jensenii 700 bp [26]
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Results
Vaginal biomarkers-semen biomarkers multiplex PCR
DNA isolated from vaginally inserted HEC gel applicators without vaginal gel
expulsion was analyzed for bacterial and semen biomarkers. Using our previously
developed semen exposure multiplex PCR, the technique was expanded to include
detection of vaginal bacteria using published primer sequences (Table 1). The
panel of vaginal bacterial species encompasses lactobacilli since this species is
highly prevalent in the vagina. Also included are non-lactobacilli which have been
reported in women with BV [15], but also in healthy women of non-Caucasian
ethnicities [13]. The chosen bacterial species needed to be undetectable in semen/
sperm DNA. This was a necessary criterion in order to specifically distinguish
vaginal insertion of the gel applicator from semen exposure, two independent
events. The final multiplex PCR, tested against semen/sperm DNA, confirmed
negative amplification of bacterial markers (Fig. 2). In these samples, the only
products amplified were the human control gene, amelogenin, and Y-
chromosomal genes, TSPY4 and SRY. The multiplex PCR was able to detect
bacterial DNA present on vaginally inserted gel applicators with or without semen
exposure (Fig. 3, Lanes 3, 5). Unlike DNA from vaginally inserted applicators, no
bacterial PCR products were amplified from an ungloved, manually handled, un-
inserted applicator (sham, Lane 2). It is important to note that amelogenin was
not amplified in DNA from a sham applicator suggesting that there were not
enough epidermal cells from the hand transferred to the applicator for
amplification of the gene in this PCR platform. Therefore, amplification of
amelogenin and bacterial marker(s) together is necessary to conclude that the
applicator was vaginally inserted. While Fig. 3 shows one bacterial species present
on the applicator, the primers in the multiplex PCR were chosen to potentially
detect different patterns of bacterial species found in different women of different
races. Fig. 4A is an example of DNA from a vaginally inserted applicator of an
African-American woman demonstrating amplification of 4 bacterial markers. An
electropherogram of the amplified bacterial markers generated by the Bioanalyzer
2100 is also included (Fig. 4B). Because of the higher resolution of the individual
PCR products, the Bioanalyzer was chosen to be the method of choice for PCR
analysis of future studies. Fig. 4C are electropherograms from applicator DNA of
two more African American women showing amplification of amelogenin plus
differing patterns of bacterial markers.
Cytokeratin 4 as a marker of cervicovaginal cells
While protein biomarkers are not as sensitive as DNA biomarkers, they offer high
specificity. As part of this composite measure of gel applicator adherence, cells
were also isolated from vaginally inserted HEC gel applicators described above. A
hematoxylin stain of the cells was done to confirm the feasibility of the method for
isolating the cells from the applicator, and the result was compared to a swabbed
sham applicator. There was a clear difference in cell numbers recovered from
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vaginally inserted and sham applicators (Fig. 5). Sham applicators do not provide
the abundance of cells, if any, that vaginally inserted applicators provide. To
further confirm that the hematoxylin stained cells were vaginal in origin, the
presence of CK4 was determined using immunocytochemistry. Published data has
demonstrated the presence of CK4 in cells from vaginal swabs, but not from
Figure 2. Lack of Bacterial Marker DNAAmplification in Semen or SpermDNA. 30 and 90 ng, respectively
of sperm DNA (lanes 1–2) and semen DNA (lanes 3–4) were used as template DNA for the expanded
multiplex PCR. No bacterial markers were amplified. Only the Y-chromosomal DNA markers, TSPY4 and
SRY, along with the internal control gene, amelogenin, were amplified. Vaginal swab DNA showing L. jensenii
amplification was used as a positive control (lane 5). Lane 6 is a PCR negative control.
doi:10.1371/journal.pone.0114368.g002
Figure 3. Representative Multiplex PCR Amplification of DNA Biomarkers from Vaginally Inserted and
Sham Applicators. Identical amounts of template DNA from sham (lane 2) and vaginally inserted (lane 3 and
5) HEC gel applicators obtained from one woman were used for the multiplex PCR. Vaginal swab DNA from
the same woman was used as a positive control (lane 4). A control applicator which was simply taken out of
the package and swabbed was also compared as a negative control (lane 1). A PCR negative control is
included (lane 6). L. gasseri was amplified in only the vaginally inserted applicator DNA and positive control
vaginal swab DNA. Semen exposure is detected as TSPY4 and SRY gene amplification (lane 5). No
amelogenin amplification is seen in the control or sham applicator (lane 1–2).
doi:10.1371/journal.pone.0114368.g003
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epidermal swabs [19]. As predicted vaginal cells recovered from an inserted
applicator were positive for CK4 while epidermal cells from the hand were not
(Fig. 6A, 6B). Cytokeratin 10 (CK10) was detected in the epidermal cells as a
positive control confirming the validity of the negative CK4 result (Fig. 6C). CK4
expression in the recovered cells is an additional and specific confirmation that
the gel applicator was vaginally inserted.
Figure 4. DNA Biomarker Panel Applies to Ethnically Diverse Populations. A) Agarose gel electrophoresis analysis showing multiplex PCR amplification
of identical amounts of template DNA from sham (lane 1) and vaginally inserted (lane 2) applicators from an African-American woman. Four bacterial
markers listed above plus amelogenin were only amplified in the DNA from a vaginally inserted HEC gel applicator and not in DNA from a sham applicator.
These bacterial markers were identical to those amplified in the corresponding vaginal swab DNA (Lane 4). A PCR negative control is also included (lane 3).
B) PCR analysis using the Bioanalyzer 2100 confirms the 4 bacterial markers and amelogenin. C) Electropherograms of DNA biomarkers from vaginally
inserted applicators from two additional African-American women demonstrating different panels of bacterial DNA markers. Peak #1 is the control gene
amelogenin, peak #2 is Prevotella buccalis-like, peak #3 is L. jensenii, and peak #4 is L. crispatus. *Non-specific primer dimers and DNA sizing markers.
doi:10.1371/journal.pone.0114368.g004
Figure 5. HematoxylinStainDiscriminatesVaginally Inserted fromShamApplicators.Swabbed cells from
applicators were isolated and fixed in Cytorich Red solution. 5 ml of the resulting 20 ml suspensions from
vaginally inserted applicators (A) and sham applicators (B) were spotted and dried overnight for staining the
next day. The number of cells transferred from the hand to applicator during handling is too low to detect cells
in a 5 ml aliquot (B).
doi:10.1371/journal.pone.0114368.g005
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Detection of DNA/protein biomarkers on stored applicators and
upon exposure to vaginal HEC gel expulsion
Logistically, it is not practical to have participants in a microbicide gel applicator
study return used applicators immediately. Therefore, we determined whether the
DNA and CK4 biomarkers could be detected from vaginally inserted applicators
after storage in the original wrappers for 30 days at room temperature. As shown
in Fig. 7, vaginal CK4 protein (A) and vaginal bacterial DNA markers (B) were
successfully detected from applicators from two women (#1, 2) stored for 30
days. Vaginal swab DNA from one of the women (‘‘VS’’) was included as a
positive control to show that the bacterial species amplified from the stored
applicator was identical to a vaginal swab from that same woman (#1).
While the data shown above confirms that biomarkers of vaginal insertion and
semen exposure can be isolated from HEC gel applicators that were inserted
without gel expulsion, it was necessary to determine if vaginally expelled HEC gel
interferes with biomarker detection. Fig. 8 shows cells from three different women
displaying positive CK4 detection when HEC gel was vaginally expelled. Fig. 9A
shows different examples of DNA biomarkers isolated from vaginally inserted and
gel expelled applicators. The pattern of bacterial biomarkers plus amelogenin from
Figure 6. Representative Cytokeratin 4 (CK4) Immunocytochemistry in Cells From Vaginally Inserted
Applicators and Hand Swabs. Cells from vaginally inserted HEC gel applicators were positive for CK4 (A)
while epidermal cells were negative (B). To confirm the quality of the epidermal cells, CK10 expression was
determined as a positive control (C); Normal rabbit or mouse IgG negative controls (inset pictures).
doi:10.1371/journal.pone.0114368.g006
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the applicators (Lane 1) was the same as those observed from vaginal swab DNA
of the same woman (Lane 3). Sham applicators handled by the women were
negative for those markers, including amelogenin (Lane 2). In addition, semen
DNA biomarkers were not affected by HEC gel (Fig. 9B).
Measurement of Residual TFV and Biomarkers on Vaginally
Inserted Applicators
The feasibility of measuring residual TFV remaining on applicators in which gel
had been discharged vaginally was also determined. TFV gel applicators, vaginally
Figure 7. DNAandCK4 Biomarkerson Applicators Stored for30days. After30days of storage at room temperature, applicators from two women (#1 and
#2) were swabbed and DNA/cells isolated. CK4 expression was positive (A) while amelogenin and bacterial markers were amplified by the multiplex PCR
(B) confirming stability of the biomarkers over the course of 30 days. Vaginal swab DNA from woman #1(‘‘VS’’) is included as a positive control to confirm
that identical amplified bacterial species were found on the applicator #1 (Lane 1). A no DNA PCR control is also included (‘‘neg’’); Normal rabbit IgG
negative control (inset pictures).
doi:10.1371/journal.pone.0114368.g007
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inserted and discharged by four women, were swabbed, and those swabs extracted
for TFV. These results were compared to sham applicators and unopened, unused
applicators (‘‘blanks’’). Table 2 demonstrates the results of the LC-MS/MS
analysis of TFV in those swabs. Swabs from all four vaginally inserted gel
applicators (#1-4) had detectable TFV. Negative controls including sham and
unused applicators (‘‘blanks’’) demonstrated no background TFV detection. Also
Figure 8. Hydroxyethylcellulose (HEC) Placebo Gel Does Not Interfere with CK4 Biomarker Detection.
HEC gel applicators were inserted and gel expelled into the vaginas of three different women. The applicators
were swabbed for analysis of CK4 expression in isolated vaginal cells. While the observed particles above
appear to be associated with the presence of gel, the cells from all three women still demonstrated positive
CK4 expression. Normal rabbit IgG negative control (inset pictures).
doi:10.1371/journal.pone.0114368.g008
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Figure 9. Hydroxyethylcellulose (HEC) PlaceboGel DoesNot InterferewithDNABiomarker Detection.A)
Different patterns of DNA biomarkers were still detected in the presence of vaginally expelled HEC gel (Lane
1). These patterns matched the corresponding patterns observed from vaginal swab DNA of those same
women (Lane 3). DNA from sham applicators manually handled by the women (Lane 2) and No DNA PCR
(Lane 4) controls were negative. B) Exposure of HEC gel did not interfere with the DNA biomarkers before
(Lane 1) or after semen exposure (Lane 2). No DNA PCR negative control is included (Lane 3).
doi:10.1371/journal.pone.0114368.g009
Table 2. Quantitation of Residual Tenofovir (TFV) on Gel Applicators.
Vaginally Inserted (#1-4) Controls
1 2 3 4 Sham1 Blank2
TFV (ng) 1120 1250 659 577 BLD3 BLD
Storage (days) 32 55 33 13 - -
1Manually handled, gel expelled in trash, n52.
2Unopened applicator, removed from foil packet only, n52.
3BLD 5 Below level of detection.
doi:10.1371/journal.pone.0114368.t002
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included in the table are the storage times of each of the applicators. Applicators
were stored at room temperature until ready for swabbing and subsequent drug
analysis. The data clearly show that residual surface TFV is detectable on vaginally
inserted applicators stored up to 55 days. This data confirms feasibility to measure
drug expulsion simultaneously with biomarkers of vaginal insertion and semen
exposure. Like HEC, TFV did not interfere in detecting biomarkers of vaginal
insertion and semen exposure. Unlike the used HEC applicators described above
which were vaginally inserted and gel expelled by the clinical investigator, the
biomarker data shown in Fig. 10 are from TFV gel applicators that were vaginally
inserted by three participants. The data also shows that DNA and CK4 biomarkers
can be detected whether the applicator was stored for 6 days (A) or 7 months (B,
C) at room temperature before being swabbed for analysis.
Discussion
Confirming product adherence and protocol compliance in microbicide HIV
prevention studies is necessary to rationally interpret the safety and efficacy of
microbicides and other HIV prevention products [2]. In addition, a common
requirement of participants in these types of studies is the use of condoms during
coital activity to prevent semen exposure, an indicator of increased HIV risk. This
report presents a composite, qualitative measurement of vaginal insertion
(protocol compliance), semen exposure (HIV risk), and drug expulsion (product
adherence) using objective biomarkers and residual drug present on vaginally
inserted gel applicators. Vaginal gel applicators were chosen to develop this
composite measure because, thus far, vaginal TFV 1% gel used before and after
coitus is the only microbicide proven to reduce the risk of HIV acquisition in
women [3]. Furthermore, this gel delivered by vaginal applicators is currently
being tested in a phase III safety and effectiveness study (FACTS001) and an open-
label study (CAPRISA008). The outcomes of these studies are clearly dependent
on adherence and protocol compliance.
We previously reported the development of a multiplex PCR system to assess
semen exposure by detecting the presence of TSPY4 and SRY, two y-chromosomal
genes [20]. Using this system as a platform, DNA biomarkers were pursued to
assess vaginal insertion of gel applicators. Similar to the Y-chromosome which is
DNA specific only to the male gender, vaginal bacteria were used as targets for
biomarkers since it could be distinguished from the ubiquitous human (female)
DNA. There is ample literature describing fluctuations in the normal vaginal
microbiome, particularly BV, using PCR or next generation sequencing [13, 15],
which establishes that Lactobacilli are the predominant bacteria in the vaginas of
premenopausal women. In addition, bacterial 16S rRNA sequences have been
investigated for identification of body fluids of forensic biological samples
[16, 17]. Therefore, we incorporated lactobacilli primers into our semen multiplex
PCR. However, the PCR must have enough markers to identify a variety of
women of different ethnicities. Studies comparing vaginal microbiomes of various
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ethnic groups have demonstrated that some groups had lower levels of lactobacilli
suggesting that a normal vaginal flora may not be as lactobacilli dominant as
previously believed [13, 14, 27]. Therefore, our multiplex PCR incorporates non-
lactobacillus species as well. The applicator data of three African-American
women presented in this report demonstrate the feasibility that the current panel
of vaginal bacteria chosen should be able to detect vaginal bacteria from women of
different races and ethnicities. This has been confirmed in a recently completed
clinical study (CONRAD D13-125), whereby bacterial DNA biomarkers were
detected on gel applicators from all 40 women, which encompassed Caucasian
and African-American races as well as Hispanic ethnicity [23]. It also confirms
that, for some women, non-lactobacillus species may predominate over
lactobacilli. Therefore, inclusion of both lactobacillus and non-lactobacillus
species is a necessary criterion for analyzing DNA-based adherence markers on
vaginally inserted applicators from larger, more diverse cohorts of women. Since
the data presented here represents women in the US, we recently started a study
investigating these bacterial biomarkers on a subset of gel applicators used by
African women who participated in the FACTS 001 study. The data generated
from this study as well as future studies currently being planned will confirm the
applicability of these biomarkers to different vaginal flora observed across diverse
populations of women.
Combining vaginal bacterial markers with Y-chromosomal markers allows
simultaneous detection of vaginal insertion of the applicator and possible semen
exposure. Some of the current methods used to determine vaginal insertion of gel
applicators employ visualization of vaginal fluid either by the naked eye under
ambient light (VIRA) [7], dyes such as trypan blue [9], or ultraviolet light (UVL)
fluorescence [7]. A major limitation of these methodologies is that the assessment
is affected by the subjectivity of the reader. While trypan blue and UVL have better
sensitivity than VIRA, they are not specific enough to distinguish between vaginal
and other fluids. It is also well known that semen, and even other biological fluids
fluoresce under UVL [28]. The particular plastic of the gel applicator being used
affects DSA methodology [29]. Sensitivity and specificity was lower for HTI
polypropylene plastic gel applicators versus polyethylene gel applicators. The data
presented in this report utilized HTI polypropylene gel applicators. Comparing
DNA and protein biomarkers with VIRA and UVL demonstrated that the overall
biomarker sensitivity and specificity of 98% and 100%, respectively, was not
hindered by this type of applicators [23].
Figure 10. TFV 1%Gel Does Not Interfere with DNA and CK4Biomarker Detection.Examples of 3 different
women that vaginally inserted and expelled TFV 1% gel applicators before returning the applicators to the
clinic. Applicators were stored in the clinic for 6 days (A) or as long as 7 months (B, C) before swabbing for
DNA and CK4 biomarkers. All showed evidence of vaginal insertion by amplification of amelogenin (peak #1)
plus bacterial markers and positive CK4 detection. The bacterial species detected are as follows: (A) #2, L.
crispatus; #3, L. jensenii; (B) #2 Prevotella buccalis-like; #3 L. jensenii; (C) #2, Prevotella buccalis-like; #3,
L.crispatus. The peak representing Prevotella buccalis-like appears very small because the Y-axis scale had
to accommodate the abundant levels of L.crispatus.
doi:10.1371/journal.pone.0114368.g010
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While DNA biomarkers provide high sensitivity, they do not always provide
high specificity as to cellular location of the biological sample. Cytokeratins are
cytoskeletal components commonly investigated for identification of not just
origin, but location of a biological sample [19]. Based on results of this previous
report, we investigated the utility of cytokeratin 4 to confirm vaginal insertion
versus manual handling (‘‘sham’’) of gel applicators. Our data agrees with the
previous report that vaginal cells on an applicator express cytokeratin 4 while
epidermal cells do not. Skin cells, as previously shown, are positive for cytokeratin
10. Vaginal cells isolated from the applicator are also positive to cytokeratin 10 to
various degrees among different women. Slight positivity of CK10 in cells from
vaginal swabs has also been observed so using CK10 for determining vaginal
versus epidermal origin is less useful [19]. The present analysis excludes the
possibility of false positives based on epidermal cells shed upon manual handling
of the gel applicator by overall cell abundance (hematoxylin stained slide) and the
presence or absence of cytokeratin 4. The very low cell yield from a manually
handled ‘‘sham’’ applicator correlates with the absence of amelogenin gene
amplification in sham applicator DNA. This observation, recently confirmed in a
larger study [23], suggests that the chance for false positives generated from
epidermal cells appears low. Therefore, even when contamination of the hand
with vaginal bacteria is possible, amelogenin plus vaginal bacteria amplification
together is indicative of vaginal insertion. Very low sample yield from the hand is
not a rare event. This type of sample has been termed by the forensics field as
‘‘Touch DNA’’, which is DNA isolated from shed skin cells transferred between
two people or between an object and person during some type of physical contact.
Because of the limited amount of sample present with this type of contact, there is
still much ongoing investigation in being able to simultaneously determine not
just a DNA profile but origin of the forensic sample [30].
The CK4 data presented in this report show variable yields of cells isolated from
vaginally inserted applicators stored at different time points ranging from 6 days
up to 7 months. Data in Fig. 10 plus unpublished observations do not
demonstrate a strong correlation between cell yield and time of applicator storage.
Current ongoing work suggests that variability in cell yield originates from the
differences in the amount of vaginal cells shed from one woman to the next.
Therefore, there is a possibility that cells shed and left on the used applicator may
be too low to detect by hematoxylin stain or CK4 immunocytochemistry (false
negatives). We believe DNA biomarkers should be able to overcome this
limitation because the stability of DNA is much higher than protein. Because of
this, additional experiments are being performed to adjust the laboratory
protocols for obtaining optimal sample yields from various levels of vaginal
material left of the applicators.
The ‘‘BAT 24’’ dosing regimen of TFV that has shown efficacy in reducing HIV
acquisition in women involves a pre-coital and post-coital dose of TFV gel [3]. In
this report, the presence of TFV or HEC gel did not affect the amplification of
DNA biomarkers or the detection of CK4 in vaginal cells. The applicators could
also be stored up to 30 days without loss of the DNA and protein biomarkers, and
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this timeframe has been successfully confirmed [23]. Preliminary data from
applicators stored 7 months under climate controlled laboratory conditions
suggest the possibility of even longer storages (Fig. 10). These results confirm the
stability of DNA and CK4 biomarkers in determining vaginal insertion of
applicators and semen exposure. Since Y-STR DNA typing has been successfully
done with vaginal swabs stored for 25 years [31], we are planning to investigate
the stability of the biomarkers upon longer storage times such as three and six
months. These investigations include planning of future clinical studies in Africa
to test the stability of the biomarkers on vaginally inserted applicators stored at
different time points under field conditions of high heat and humidity. This is
particularly important for CK4 analysis since proteins are less stable. The
feasibility of adding a third swab to the current protocol for measuring residual
TFV concentrations on vaginally inserted applicators was tested. Our results from
vaginally inserted applicators for which TFV gel was expelled confirms that
residual TFV swabbed off of the applicators stored up to 55 days can be detected
by LC-MS/MS techniques. In addition, TFV was not detected on sham applicators
suggesting that vaginal drug expulsion can be distinguished from sham
applicators. This initial data has led to current, ongoing investigation to
determine whether this approach can determine pre-coital versus post-coital gel
expulsion.
This biomarker approach for determining adherence has been specifically
designed for an applicator type of drug/gel delivery. It is still yet to be determined
whether different aspects of the approach can be utilized for other delivery
systems. This question is currently under intense investigation. Another
requirement for achieving the most accurate interpretation of the data is the
necessity that clinical studies utilizing this approach incorporate a vaginal swab
positive control into the design. This requirement is important because the
environment is an obvious source of bacteria. This potential source of external
contamination plus the high sensitivity of the PCR technology increase chances
that some amplified bacterial markers may not originate from the vagina.
However, DNA isolated from the vaginal swab would confirm which species
originated from the vagina. This is also necessary for DNA biomarkers alone to
determine vaginal insertion when yields of isolated vaginal cells are too low or of
low quality to confirm vaginal origin via CK4 immunocytochemistry. While the
data presented here and our completed pilot study [23] demonstrate very good
ability to distinguish sham handling versus vaginal insertion, the composite
measure does not provide time-specific information of applicator use. In other
words, we cannot definitely determine that the participant utilized the gel
according to the BAT24 protocol versus feigning adherence by potentially
inserting all applicators at one time point before returning to the clinic.
Completing the development and validation of drug expulsion through LC-MS/
MS will help provide an answer to this question. As it currently stands, this
qualitative assessment of adherence objectively determines that applicators were
vaginally inserted without total dependency on self-reports of sex acts and with
less subjectivity of data interpretation.
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In summary, we present an objective approach using DNA and protein
biomarkers plus drug detection to determine vaginal insertion of gel applicators,
semen exposure, and drug expulsion from a single returned applicator. Consistent
and correct use of microbicides is needed to provide appropriate protection from
HIV transmission [32]. Therefore, biomarkers of adherence are extremely
desirable because data shows that subjective markers of adherence are unreliable.
It is clear that some of the recent large phase III trials of PrEP products have failed
to show product effectiveness due to low adherence [33, 34] because only a low
percentage of blood samples showed detectable drug levels. It is therefore possible
that many of the previous topical microbicides trials, which failed to show
product effectiveness but for which we do not have objective markers of
adherence, may have suffered from the same problem [35–37]. Solid adherence
data utilizing more objective measures would enable the implementation of
alternative trial designs based on high-adherence population enrichment.
Various delivery systems of microbicides are being developed and tested
because women vary in their preferences, social context and sexual behavior, and
these factors affect product adherence and effectiveness [38]. Future studies
expanding the use of DNA and protein biomarkers of adherence can also aid in
confirming subjective, self-reports of high or low acceptability to eventually
develop better products that will be used successfully for HIV protection.
Acknowledgments
We acknowledge the Clinical Research Center of Eastern Virginia Medical School
and the UNC Center for AIDS Research.
Author Contributions
Conceived and designed the experiments: TJ GD. Performed the experiments: TJ
AN. Analyzed the data: TJ AN AK GD. Contributed reagents/materials/analysis
tools: AT AK DA GD. Wrote the paper: TJ AK GD. Editorial comments/critiques:
AN AT AK DA.
References
1. WHO HIV/AIDS Fact sheet. October 2013; Available: http://www.who.int/medicentre/factsheets/fs360/
en/index.html.
2. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR (2012) Unraveling the divergent results
of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13–19.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness
and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science 329: 1168–1174.
4. Karim SS, Kashuba AD, Werner L, Karim QA (2011) Drug concentrations after topical and oral
antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378: 279–281.
Objective Markers of Microbicide Adherence
PLOS ONE | DOI:10.1371/journal.pone.0114368 December 9, 2014 20 / 22
5. Dai JY, Gilbert PB, Hughes JP, Brown ER (2013) Estimating the efficacy of preexposure prophylaxis
for HIV prevention among participants with a threshold level of drug concentration. Am J Epidemiol 177:
256–263.
6. Gallo MF, Behets FM, Steiner MJ, Thomsen SC, Ombidi W, et al. (2007) Validity of self-reported ‘safe
sex’ among females sex workers in Mombasa, Kenya—PSA analysis. International Journal of STD &
AIDS 18: 33–38.
7. Moench TR, O’Hanlon DE, Cone RA (2012) Evaluation of microbicide gel adherence monitoring
methods. Sex Transm Dis 39: 335–340.
8. Hemmerling A, Harrison WG, Brown JM, Moscicki B, Oziemkowska M, et al. (2012) Trypan blue
staining to determine vaginal exposure in two types of plastic vaginal applicators containing two different
microbicide formulations. Sex Transm Dis 39: 710–712.
9. Katzen LL, Fernandez-Romero JA, Sarna A, Murugavel KG, Gawarecki D, et al. (2011) Validation of
a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm
Dis 38: 1050–1055.
10. Keller MJ, Buckley N, Katzen LL, Walsh J, Friedland B, et al. (2013) Use of the dye stain assay and
ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex
Transm Dis 40: 939–943.
11. van der Straten A, Cheng H, Mensch B, Friedland B, Katzen L, et al. (2013) Evaluation of 3
approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis 40: 950–
956.
12. Gengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, et al. (2014) Monitoring microbicide gel
use with real-time notification of the container’s opening events: results of the CAPRISAWisebag study.
AIDS Behav 18: 833–840.
13. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, et al. (2011) Vaginal microbiome of reproductive-
age women. Proc Natl Acad Sci U S A 108 Suppl 1: 4680–4687.
14. Lamont RF, Sobel JD, Akins RA, Hassan SS, Chaiworapongsa T, et al. (2011) The vaginal
microbiome: new information about genital tract flora using molecular based techniques. BJOG 118:
533–549.
15. Fredricks DN, Fiedler TL, Thomas KK, Oakley BB, Marrazzo JM (2007) Targeted PCR for Detection
of Vaginal Bacteria Associated with Bacterial Vaginosis. Journal of Clinical Microbiology 45: 3270–3276.
16. Akutsu T, Motani H, Watanabe K, Iwase H, Sakurada K (2012) Detection of bacterial 16S ribosomal
RNA genes for forensic identification of vaginal fluid. Leg Med (Tokyo) 14: 160–162.
17. Fleming RI, Harbison S (2010) The use of bacteria for the identification of vaginal secretions. Forensic
Sci Int Genet 4: 311–315.
18. Benschop CCG, Quaak FCA, Boon ME, Sijen T, Kuiper I (2012) Vaginal microbial flora analysis by
next generation sequencing and microarrays; can microbes indicate vaginal origin in a forensic context?
International Journal of Legal Medicine 126: 303–310.
19. Schulz MM, Buschner M, Leidig R, Wehner HD, Fritz P, et al. (2010) A new approach to the
investigation of sexual offenses-Cytoskeleton anlysis reveals the origin of cells found on forensic swabs.
Journal of Forensic Sciences 55: 492–498.
20. Jacot TA, Zalenskaya I, Mauck C, Archer DF, Doncel GF (2013) TSPY4 is a novel sperm-specific
biomarker of semen exposure in human cervicovaginal fluids; potential use in HIV prevention and
contraception studies. Contraception 88: 387–395.
21. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, et al. (2011) A multi-compartment,
single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.
PLoS One 6: e25974.
22. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011) Penetration of tenofovir and
emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 3:
112re114.
23. Thurman AR, Jacot T, Kimble T, Mauck C, Nelson A, et al. (2014) Comparison of visual and ultraviolet
light inspection versus DNA/protein biomarkers to assess product adherence with vaginal microbicide
applicators. Sex Transm Dis, Accepted for publication.
Objective Markers of Microbicide Adherence
PLOS ONE | DOI:10.1371/journal.pone.0114368 December 9, 2014 21 / 22
24. Fredricks DN, Fiedler TL, Marrazzo JM (2005) Molecular identification of bacteria associated with
bacterial vaginosis. N Engl J Med 353: 1899–1911.
25. Zozaya-Hinchliffe M, Lillis R, Martin DH, Ferris MJ (2010) Quantitative PCR assessments of bacterial
species in women with and without bacterial vaginosis. J Clin Microbiol 48: 1812–1819.
26. Song Y, Kato N, Liu C, Matsumiya Y, Kato H, et al. (2000) Rapid identification of 11 human intestinal
Lactobacillus species by multiplex PCR assays using group- and species-specific primers derived from
the 16S-23S rRNA intergenic spacer region and its flanking 23S rRNA. FEMS Microbiol Lett 187: 167–
173.
27. Zhou X, Brown CJ, Abdo Z, Davis CC, Hansmann MA, et al. (2007) Differences in the composition of
vaginal microbial communities found in healthy Caucasian and black women. ISME J 1: 121–133.
28. Virkler K, Lednev IK (2009) Analysis of body fluids for forensic purposes: from laboratory testing to non-
destructive rapid confirmatory identification at a crime scene. Forensic Sci Int 188: 1–17.
29. Austin MN, Rabe LK, Hillier SL (2009) Limitations of the dye-based method for determining vaginal
applicator use in microbicide trials. Sex Transm Dis 36: 368–371.
30. Hanson E, Haas C, Jucker R, Ballantyne J (2012) Specific and sensitive mRNA biomarkers for the
identification of skin in ‘touch DNA’ evidence. Forensic Sci Int Genet 6: 548–558.
31. Honda K, Roewer L, de Knijff P (1999) Male DNA typing from 25-year-old vaginal swabs using Y
chromosomal STR polymorphisms in a retrial request case. J Forensic Sci 44: 868–872.
32. Mauck CK, van der Straten A (2008) Using objective markers to assess participant behavior in HIV
prevention trials of vaginal microbicides. Journal of Acquired Immune Deficiency Syndromes 49: 64–69.
33. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for
HIV infection among African women. N Engl J Med 367: 411–422.
34. Marazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure prophylaxis for HIV in
women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study; 2013.
35. Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, et al. (2008) Effectiveness of cellulose
sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One 3:
e3784.
36. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Gehret Plagianos M, et al. (2008) Efficacy of
Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind,
placebo-controlled trial. Lancet 372: 1977–1987.
37. Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, et al. (2011) Safety and
effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25:
957–966.
38. Woodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, et al. (2013) Microbicide clinical trial
adherence: insights for introduction. J Int AIDS Soc 16: 18505.
Objective Markers of Microbicide Adherence
PLOS ONE | DOI:10.1371/journal.pone.0114368 December 9, 2014 22 / 22
